출혈성 뇌졸중 치료 기기 시장 규모, 점유율, 동향 분석 보고서 : 치료 유형별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Hemorrhagic Stroke Treatment Devices Market Summary

The global hemorrhagic stroke treatment devices market size was valued at USD 1.19 billion in 2025 and is projected to reach USD 2.08 billion by 2033, growing at a CAGR of 7.24% from 2026 to 2033. The industry is driven by the rising incidence of intracerebral hemorrhage and cerebral aneurysms, particularly among aging populations and patients with hypertension.

Increasing adoption of minimally invasive neurointerventional procedures and expansion of comprehensive stroke centers are further boosting demand. In addition, technological advancements, improving clinical outcomes, and supportive reimbursement in developed healthcare systems are accelerating market growth. The rising incidence of intracerebral hemorrhage and cerebral aneurysms increases the number of patients requiring urgent medical intervention, directly boosting demand for hemorrhagic stroke treatment devices. As more cases are diagnosed, healthcare providers adopt advanced endovascular and minimally invasive technologies to improve outcomes, which in turn drives market growth and encourages continued innovation and investment in treatment solutions.

Multiple countries across Europe continue to report a significant hemorrhagic stroke burden, contributing to anticipated market expansion.

According to the Global Stroke Fact Sheet 2025 published by the World Stroke Organization, more than 12 million new stroke cases occur annually, and nearly one in four people worldwide will experience a stroke during their lifetime. The report indicates that intracerebral hemorrhage (ICH) accounts for 28.8% and subarachnoid hemorrhage (SAH) for 5.8% of all incident strokes, underscoring the substantial hemorrhagic stroke burden. The growing prevalence of this disease is anticipated to be a key factor supporting market growth during the forecast period.

According to data published by the American Heart Association in February 2022, hemorrhagic strokes account for approximately 10% of the nearly 800,000 stroke cases reported annually in the U.S., and they are associated with a higher mortality rate compared to other stroke types. This considerable disease burden is anticipated to drive demand for hemorrhagic stroke treatment devices.

Hemorrhagic Stroke Treatment Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hemorrhagic stroke treatment devices market report on the basis of treatment type, end use, and region:

• Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
• Aneurysm & Hemorrhagic Stroke Interventions
  • By Indication
  • Intracranial Aneurysm
  • cSDH (MMA Embolization)
  • AVM & AVF Embolization
  • By Device
  • Embolization Coiling Systems
  • Bare Platinum Coils
  • Coated / Bioactive Coils
  • Flow Diversion Systems
  • Standard Flow-Diverting Stents (e.g., Pipeline)
  • Next-Generation / Surface-Modified Flow Diverters
  • Intrasaccular Flow Disruption Devices
  • Woven EndoBridge (WEB)
  • Contour Neurovascular System
  • Luna Aneurysm Embolization System
  • Liquid Embolization Agents
  • Non-Adhesive Liquid Embolics (Onyx, Squid, PHIL)
  • Adhesive Liquid Embolics (NBCA)
• Cerebral Angioplasty & Vascular Remodeling
  • Balloon Angioplasty Systems
  • Intracranial & Carotid Stenting Systems
  • Coil-Assisted Adjunctive Devices (Balloon-assisted and stent-assisted)
• Ancillary & Procedural Access Devices
  • Guiding & Distal Access Catheters
  • Microcatheters
  • Access Sheaths & Wires
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Specialty Neurosurgery Centers
• Ambulatory Surgical Centers
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Treatment Type
  • 1.1.2. End Use
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
  • 1.5.1. Data for primary interviews in North America
  • 1.5.2. Data for primary interviews in Europe
  • 1.5.3. Data for primary interviews in Asia Pacific
  • 1.5.4. Data for primary interviews in Latin America
  • 1.5.5. Data for Primary interviews in MEA
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Hemorrhagic Stroke Treatment Devices Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rising prevalence of intracranial aneurysms and hemorrhagic stroke
    • 3.2.1.2. Advancements in neurointerventional technologies
    • 3.2.1.3. Growing adoption of endovascular procedures
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. High cost of devices and procedures
    • 3.2.2.2. Limited availability of skilled neurointerventional specialists
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Technological innovation in minimally invasive neurointerventional devices
    • 3.2.3.2. Rising public awareness about hemorrhagic stroke
    • 3.2.3.3. Increasing clinical trials
    • 3.2.3.4. Expansion of stroke care infrastructure in emerging markets
    • 3.2.3.5. Rising stroke incidence among younger adults
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Complications associated with neurovascular treatments
    • 3.2.4.2. Balancing innovation with safety requirements
• 3.3. Hemorrhagic Stroke Treatment Devices Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Hemorrhagic Stroke Treatment Devices Market: Treatment Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Hemorrhagic Stroke Treatment Devices Market: Treatment Type Movement Analysis, 2025 & 2033 (USD Million)
• 4.3. Global Hemorrhagic Stroke Treatment Devices Market Size & Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million)
• 4.4. Aneurysm & Hemorrhagic Stroke Interventions
  • 4.4.1. Aneurysm & hemorrhagic stroke interventions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. By indication
    • 4.4.2.1. By indication market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.2. Intracranial aneurysm
      • 4.4.2.2.1. Intracranial aneurysm market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.3. cSDH (MMA Embolization)
      • 4.4.2.3.1. cSDH (MMA Embolization) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.4. AVM & AVF embolization
      • 4.4.2.4.1. AVM & AVF embolization market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. By device
    • 4.4.3.1. By device market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.3.2. Embolization coiling systems
      • 4.4.3.2.1. Embolization coiling systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.2.2. Bare Platinum Coils
        • 4.4.3.2.2.1. Bare Platinum Coils market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.2.3. Coated / Bioactive Coils
        • 4.4.3.2.3.1. Coated / Bioactive Coils market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.3.3. Flow diversion systems
      • 4.4.3.3.1. Flow diversion systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.3.2. Standard Flow-Diverting Stents (e.g., Pipeline)
        • 4.4.3.3.2.1. Standard Flow-Diverting Stents (e.g., Pipeline) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.3.3. Next-Generation / Surface-Modified Flow Diverters
        • 4.4.3.3.3.1. Next-Generation / Surface-Modified Flow Diverters market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.3.4. Intrasaccular flow disruption devices
      • 4.4.3.4.1. Intrasaccular flow disruption devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.4.2. Woven EndoBridge (WEB)
        • 4.4.3.4.2.1. Woven EndoBridge (WEB) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.4.3. Contour Neurovascular System
        • 4.4.3.4.3.1. Contour Neurovascular System market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.4.4. Luna Aneurysm Embolization System
        • 4.4.3.4.4.1. Luna Aneurysm Embolization System market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.3.5. Liquid embolization agents
      • 4.4.3.5.1. Liquid embolization agents market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.5.2. Non-Adhesive Liquid Embolics (Onyx, Squid, PHIL)
        • 4.4.3.5.2.1. Non-Adhesive Liquid Embolics (Onyx, Squid, PHIL) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.5.3. Adhesive Liquid Embolics (NBCA)
        • 4.4.3.5.3.1. Adhesive Liquid Embolics (NBCA) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Cerebral Angioplasty & Vascular Remodeling
  • 4.5.1. Cerebral angioplasty & vascular remodeling market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Balloon angioplasty systems
    • 4.6.2.1. Balloon angioplasty systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Intracranial & carotid stenting systems
    • 4.6.3.1. Intracranial & carotid stenting systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Coil-assisted adjunctive devices (Balloon-assisted and stent-assisted)
    • 4.6.4.1. Coil-assisted adjunctive devices (Balloon-assisted and stent-assisted) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Ancillary & procedural access devices
  • 4.6.1. Ancillary & procedural access devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Guiding & distal access catheters
    • 4.7.2.1. Guiding & distal access catheters market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6.3. Microcatheters
    • 4.7.3.1. Microcatheters market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6.4. Access sheaths & wires
    • 4.7.4.1. Access sheaths & wires market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Hemorrhagic Stroke Treatment Devices Market: End Use Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Hemorrhagic Stroke Treatment Devices Market: End use Movement Analysis, 2025 & 2033 (USD Million)
• 5.3. Global Hemorrhagic Stroke Treatment Devices Market Size & Trend Analysis, by End use 2021 to 2033 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Specialty Neurosurgery Centers
  • 5.5.1. Specialty neurosurgery centers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. Ambulatory Surgical Centers
  • 5.6.1. Ambulatory surgical centers market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Hemorrhagic Stroke Treatment Devices Market: Regional Estimates & Trend Analysis by Treatment Type, and End Use

• 6.1. Regional Dashboard
• 6.2. Market Size and Trend Analysis, 2021 to 2033
• 6.3. North America
  • 6.3.1. North America hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Competitive scenario
    • 6.3.2.3. Regulatory framework
    • 6.3.2.4. Reimbursement scenario
    • 6.3.2.5. U.S. hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Competitive scenario
    • 6.3.3.3. Regulatory framework
    • 6.3.3.4. Reimbursement scenario
    • 6.3.3.5. Canada hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.3.4. Mexico
    • 6.3.4.1. Key country dynamics
    • 6.3.4.2. Competitive scenario
    • 6.3.4.3. Regulatory framework
    • 6.3.4.4. Reimbursement scenario
    • 6.3.4.5. Mexico hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.4. Europe
  • 6.4.1. Europe hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Competitive scenario
    • 6.4.2.3. Regulatory framework
    • 6.4.2.4. Reimbursement scenario
    • 6.4.2.5. UK hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Competitive scenario
    • 6.4.3.3. Regulatory framework
    • 6.4.3.4. Reimbursement scenario
    • 6.4.3.5. Germany hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Competitive scenario
    • 6.4.4.3. Regulatory framework
    • 6.4.4.4. Reimbursement scenario
    • 6.4.4.5. France hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Competitive scenario
    • 6.4.5.3. Regulatory framework
    • 6.4.5.4. Reimbursement scenario
    • 6.4.5.5. Italy hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Competitive scenario
    • 6.4.6.3. Regulatory framework
    • 6.4.6.4. Reimbursement scenario
    • 6.4.6.5. Spain hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Competitive scenario
    • 6.4.7.3. Regulatory framework
    • 6.4.7.4. Reimbursement scenario
    • 6.4.7.5. Sweden hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Competitive scenario
    • 6.4.8.3. Regulatory framework
    • 6.4.8.4. Reimbursement scenario
    • 6.4.8.5. Denmark hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.9. Norway
    • 6.4.9.1. Key country dynamics
    • 6.4.9.2. Competitive scenario
    • 6.4.9.3. Regulatory framework
    • 6.4.9.4. Reimbursement scenario
    • 6.4.9.5. Norway hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Asia Pacific hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Competitive scenario
    • 6.5.2.3. Regulatory framework
    • 6.5.2.4. Reimbursement scenario
    • 6.5.2.5. China hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Japan
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Competitive scenario
    • 6.5.3.3. Regulatory framework
    • 6.5.3.4. Reimbursement scenario
    • 6.5.3.5. Japan hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Competitive scenario
    • 6.5.4.3. Regulatory framework
    • 6.5.4.4. Reimbursement scenario
    • 6.5.4.5. India hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Competitive scenario
    • 6.5.5.3. Regulatory framework
    • 6.5.5.4. Reimbursement scenario
    • 6.5.5.5. South Korea hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. Australia
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Competitive scenario
    • 6.5.6.3. Regulatory framework
    • 6.5.6.4. Reimbursement scenario
    • 6.5.6.5. Australia hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Thailand
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Competitive scenario
    • 6.5.7.3. Regulatory framework
    • 6.5.7.4. Reimbursement scenario
    • 6.5.7.5. Thailand hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Latin America
  • 6.6.1. Latin America hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Competitive scenario
    • 6.6.2.3. Regulatory framework
    • 6.6.2.4. Reimbursement scenario
    • 6.6.2.5. Brazil hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Competitive scenario
    • 6.6.3.3. Regulatory framework
    • 6.6.3.4. Reimbursement scenario
    • 6.6.3.5. Argentina hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.7. Middle East and Africa
  • 6.7.1. Middle East and Africa hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Competitive scenario
    • 6.7.2.3. Regulatory framework
    • 6.7.2.4. Reimbursement scenario
    • 6.7.2.5. South Africa hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Saudi Arabia
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Competitive scenario
    • 6.7.3.3. Regulatory framework
    • 6.7.3.4. Reimbursement scenario
    • 6.7.3.5. Saudi Arabia hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Competitive scenario
    • 6.7.4.3. Regulatory framework
    • 6.7.4.4. Reimbursement scenario
    • 6.7.4.5. UAE hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Competitive scenario
    • 6.7.5.3. Regulatory framework
    • 6.7.5.4. Reimbursement scenario
    • 6.7.5.5. Kuwait hemorrhagic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Market Share Analysis, 2025
• 7.4. Company Heat Map Analysis
• 7.5. Strategy Mapping
  • 7.5.1. Expansion
  • 7.5.2. Mergers & Acquisition
  • 7.5.3. Partnerships & Collaborations
  • 7.5.4. New Treatment Type Launches
  • 7.5.5. Research And Development
  • 7.5.6. Company Profiles
  • 7.5.7. Medtronic
    • 7.5.7.1. Company overview
    • 7.5.7.2. Financial performance
    • 7.5.7.3. Treatment Type Benchmarking
    • 7.5.7.4. Strategic initiatives
  • 7.5.8. MicroVention, Inc. (Terumo Corporation)
    • 7.5.8.1. Company overview
    • 7.5.8.2. Financial performance
    • 7.5.8.3. Treatment Type Benchmarking
    • 7.5.8.4. Strategic initiatives
  • 7.5.9. Balt
    • 7.5.9.1. Company overview
    • 7.5.9.2. Financial performance
    • 7.5.9.3. Treatment Type Benchmarking
    • 7.5.9.4. Strategic initiatives
  • 7.5.10. Scientia Vascular, Inc.
    • 7.5.10.1. Company overview
    • 7.5.10.2. Financial performance
    • 7.5.10.3. Treatment Type Benchmarking
    • 7.5.10.4. Strategic initiatives
  • 7.5.11. MicroPort Scientific Corporation
    • 7.5.11.1. Company overview
    • 7.5.11.2. Financial performance
    • 7.5.11.3. Treatment Type Benchmarking
    • 7.5.11.4. Strategic initiatives
  • 7.5.12. Johnson & Johnson (MedTech)
    • 7.5.12.1. Company overview
    • 7.5.12.2. Financial performance
    • 7.5.12.3. Treatment Type Benchmarking
    • 7.5.12.4. Strategic initiatives
  • 7.5.13. phenox GmbH (Wallaby Medical)
    • 7.5.13.1. Company overview
    • 7.5.13.2. Financial performance
    • 7.5.13.3. Treatment Type Benchmarking
    • 7.5.13.4. Strategic initiatives
  • 7.5.14. Acandis GmbH
    • 7.5.14.1. Company overview
    • 7.5.14.2. Financial performance
    • 7.5.14.3. Treatment Type Benchmarking
    • 7.5.14.4. Strategic initiatives
  • 7.5.15. B. Braun SE
    • 7.5.15.1. Company overview
    • 7.5.15.2. Financial performance
    • 7.5.15.3. Treatment Type Benchmarking
    • 7.5.15.4. Strategic initiatives
  • 7.5.16. Integra LifeSciences
    • 7.5.16.1. Company overview
    • 7.5.16.2. Financial performance
    • 7.5.16.3. Treatment Type Benchmarking
    • 7.5.16.4. Strategic initiatives
  • 7.5.17. Infinity Neuro LLC
    • 7.5.17.1. Company overview
    • 7.5.17.2. Financial performance
    • 7.5.17.3. Treatment Type Benchmarking
    • 7.5.17.4. Strategic initiatives
  • 7.5.18. Penumbra, Inc.
    • 7.5.18.1. Company overview
    • 7.5.18.2. Financial performance
    • 7.5.18.3. Treatment Type Benchmarking
    • 7.5.18.4. Strategic initiatives
  • 7.5.19. Boston Scientific Corporation
    • 7.5.19.1. Company overview
    • 7.5.19.2. Financial performance
    • 7.5.19.3. Treatment Type Benchmarking
    • 7.5.19.4. Strategic initiatives
  • 7.5.20. Stryker
    • 7.5.20.1. Company overview
    • 7.5.20.2. Financial performance
    • 7.5.20.3. Treatment Type Benchmarking
    • 7.5.20.4. Strategic initiatives
  • 7.5.21. Peter LAZIC GmbH
    • 7.5.21.1. Company overview
    • 7.5.21.2. Financial performance
    • 7.5.21.3. Treatment Type Benchmarking
    • 7.5.21.4. Strategic initiatives